Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer | Zendy

PETRI ANETTE LYKKE | Zendy; HØGDALL ESTRID | Zendy; CHRISTENSEN IB JARLE | Zendy; KJAER SUSANNE KRÜGER | Zendy; BLAAKÆR JAN | Zendy; HØGDALL CLAUS KIM | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer

Author(s) -

PETRI ANETTE LYKKE,

HØGDALL ESTRID,

CHRISTENSEN IB JARLE,

KJAER SUSANNE KRÜGER,

BLAAKÆR JAN,

HØGDALL CLAUS KIM

Publication year - 2006

Publication title -

apmis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.909

H-Index - 88

eISSN - 1600-0463

pISSN - 0903-4641

DOI - 10.1111/j.1600-0463.2006.apm_397.x

Subject(s) - medicine , stage (stratigraphy) , epithelial ovarian cancer , ovarian cancer , oncology , gynecology , cancer , gastroenterology , paleontology , biology

The purpose of the present study was to evaluate preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer (EOC). Preoperative serum CA125 levels from 118 women with FIGO (International Federation of Gynaecology and Obstetrics) stage I EOC were analysed and the prognostic value was evaluated and compared with other prognostic factors (age, grade, substages, histologic type). By the Kaplan‐Meier estimate we demonstrated that patients with stage I EOC and preoperative serum CA125 levels <65 U/mL had a significantly longer survival compared to stage I EOC patients with preoperative serum CA125≥65 U/mL (p=0.01). The results from the present study may be useful for decision making respecting postoperative chemotherapy in stage I EOC patients. Serum CA125 levels might therefore be included as a prognostic factor in future clinical trials of stage I EOC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research